Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL
Share this @internewscast.com

A new fat-busting drug that is available as a jab or tablet helps patients lose up to a quarter of their body weight, studies suggest.

People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of treatment.

And those taking daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks, the early stage trials found.

Weight loss jabs have been hailed as transformative by NHS leaders.

But tablets could be the next big breakthrough in the nation’s fight against obesity as they are likely to appeal to a wider audience who are uncomfortable with injecting themselves.

An estimated 1.5million Britons use weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions.

GPs will be able to dish out fat jabs from next week.

Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body—GLP-1 and the amylin receptor.

Those taking daily amycretin tablets lost an average of 13.1 per cent of their body weight after 12 weeks. Stock image

Those taking daily amycretin tablets lost an average of 13.1 per cent of their body weight after 12 weeks. Stock image

In comparison to amycretin, trials pivotal to getting semaglutide—the ingredient behind Ozempic—approved, show it helped users shed up to 15 per cent of their body weight over 68 weeks.

And studies have found rival jab Mounjaro can help obese people lose up to 22.5 per cent of their body weight in 72 weeks.

The new amycretin trial involved 125 adults, who took weekly injections of the drug. 

Those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs in improving blood sugar levels.

Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment, according to findings published in medical journal The Lancet.

‘These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,’ the authors wrote.

‘Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.’

The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks.

There were mild to moderate side effects including loss of appetite, nausea and vomiting.

Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months.

The authors wrote: ‘Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity.

‘Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.’

The studies were also presented at the American Diabetes Association’s Scientific Sessions in Chicago, in the US.

It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses.

Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.

GLP-1 injections suffered global shortages after celebrity users sparked a surge in popularity and the NHS has warned people against buying them from unauthorised sources.

Professor Sir Stephen Powis, national medical director at NHS England, last week told the NHS ConfedExpo conference in Manchester that weight loss jabs could be doled out as widely as statins if competition in the market brings their price down

The country’s top doctor warned obesity costs the NHS £11.4billion every year and described the financial burden as ‘unsustainable’.

From Monday, GPs will be able to prescribe the fat jab mounjaro – also known as tirzepatide – for the first time, in what he labelled an ‘exciting milestone’.

Share this @internewscast.com
You May Also Like

My Husband Couldn’t Get Out of Bed—Everything Changed for Us Instantly

Nobody asked us how we were or how we were coping with…

Experts Alert: Dangerous Parasites Infecting Humans in the US and Spreading Deadly Diseases

Bugs in the southeastern US may be spreading deadly, disease-causing parasites, experts…

How frequently a microbiologist suggests you should wash your bedding

A microbiologist has revealed exactly how often we should be washing our…

Wes Streeting Addresses Potential Doctor Strikes – What It Means for You

The British Medical Association (BMA) has revealed plans for resident doctors, previously…

I encountered the dreaded restroom sign; doctors dismissed me, and I was too embarrassed to press further. It took five years to uncover the shocking truth.

It took doctors five years to diagnose my colorectal cancer, and when…

The Lesser-Known Nutrient That Combats Fatigue and Enhances Well-Being

Over the years, the body’s capacity to transform CoQ10 into ubiquinol diminishes…

Two Popular British Foods That Help Reduce Blood Pressure

Drinking tea and nibbling on dark chocolate could boost your heart health.…

Dr. Hilary Jones Reveals Unique Method to Improve Mood Swings and Reduce Blood Pressure

TV doctor Hilary Jones has shed light on an “unusual tactic” that…

Chris’s Struggle to Save His Wife Amidst Medical Oversight: Vital Lessons for Every Family

Chris Yates pleaded with nurses and counselors to save his wife’s life.…

Man Loses Leg Due to First Aid Error

A father-of-one has told how he was forced to have his leg…

Over-the-Counter Supplement Helps 8-Year-Old Regain Ability to Walk

A compound that can make a common over-the-counter supplement has given an…

Alarming Rise in Criminalization of High-Risk HIV Groups Due to New Strict Laws Worldwide

People at higher risk of HIV, such as gay men and people…